Fig. 4. Antitumor effects of the combined treatment of sorafenib and an adenovirus co-expressing shTGF-β and shHSP27 in BALB/c nude mice. (A) SNU-449 tumors were grown in male BALB/c nude mice. Tumors were established by subcutaneous injection of 1×107 cells and were allowed to grow to an average size of 60–100 mm3. PBS and adenoviruses were intratumorally injected every other day for a total of 3 injections. Sorafenib (30 mg/kg) was administered via gavage once daily from days 1 to 10. Tumor growth was measured every 2 days for more than 19 days using calipers. (B) Survival rates were calculated every 2 days for more than 19 days. TGF-β, transforming growth factor-β; NC, negative control; PBS, phosphate buffered saline.
